AMAdelphe M. Mfuh

Adelphe M. Mfuh

*This is an algorithmically generated author record based on publicly available information.

Adelphe M. Mfuh has a total of 100 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers

    Discovery and Optimization of Pyrazine Carboxamide AZ3246, a Selective HPK1 Inhibitor

    by Jason D. Shields, David Baker, Amber Y. S. Balazs, Gayathri Bommakanti, Robert Casella, Shenggen Cao, Steve Cook, Randolph A. Escobar, Stephen Fawell, Francis D. Gibbons, et al.

    Hematopoietic progenitor kinase 1 (HPK1) is a negative regulator of the T cell receptor signaling pathway and is therefore a target of interest for immunooncology. Nonselective HPK1 inhibitors may affect other kinase components of T cell activation, blunting the beneficial impact of enhanced T cell activity that results from HPK1 inhibition itself. Here, we report the discovery of pyrazine carboxamide HPK1 inhibitors and their optimization through structure-based drug design to afford a highly selective HPK1 inhibitor, compound 24 (AZ3246). This compound induces IL-2 secretion in T cells with an EC50 of 90 nM without inhibiting antagonistic kinases, exhibits pharmacokinetic properties consistent with oral dosing, and demonstrates antitumor activity in the EMT6 syngeneic mouse model.


  • Accelerated Discovery of Carbamate Cbl-b Inhibitors Using Generative AI Models and Structure-Based Drug Design

    by Taylor R. Quinn, Kathryn A. Giblin, Clare Thomson, Jeffrey A. Boerth, Gayathri Bommakanti, Erin Braybrooke, Christina Chan, Alex J. Chinn, Erin Code, Caifeng Cui, et al.

    Casitas B-lymphoma proto-oncogene-b (Cbl-b) is a RING finger E3 ligase that has an important role in effector T cell function, acting as a negative regulator of T cell, natural killer (NK) cell, and B cell activation. A discovery effort toward Cbl-b inhibitors was pursued in which a generative AI design engine, REINVENT, was combined with a medicinal chemistry structure-based design to discover novel inhibitors of Cbl-b. Key to the success of this effort was the evolution of the "Design" phase of the Design-Make-Test-Analyze cycle to involve iterative rounds of an in silico structure-based drug design, strongly guided by physics-based affinity prediction and machine learning DMPK predictive models, prior to selection for synthesis. This led to the accelerated discovery of a potent series of carbamate Cbl-b inhibitors.


  • Discovery, Optimization, and Biological Evaluation of Arylpyridones as Cbl-b Inhibitors

    by Adelphe M. Mfuh, Jeffrey A. Boerth, Gayathri Bommakanti, Christina Chan, Alex J. Chinn, Erin Code, Patrick J. Fricke, Kathryn A. Giblin, Andrea Gohlke, Catherine Hansel, et al.

    Casitas B-lymphoma proto-oncogene-b (Cbl-b), a member of the Cbl family of RING finger E3 ubiquitin ligases, has been demonstrated to play a central role in regulating effector T-cell function. Multiple studies using gene-targeting approaches have provided direct evidence that Cbl-b negatively regulates T, B, and NK cell activation via a ubiquitin-mediated protein modulation. Thus, inhibition of Cbl-b ligase activity can lead to immune activation and has therapeutic potential in immuno-oncology. Herein, we describe the discovery and optimization of an arylpyridone series as Cbl-b inhibitors by structure-based drug discovery to afford compound 31. This compound binds to Cbl-b with an IC50 value of 30 nM and induces IL-2 production in T-cells with an EC50 value of 230 nM. Compound 31 also shows robust intracellular target engagement demonstrated through inhibition of Cbl-b autoubiquitination, inhibition of ubiquitin transfer to ZAP70, and the cellular modulation of phosphorylation of a downstream signal within the TCR axis.